ClinicalTrials.gg
RecruitingNCT04725903Updated Feb 17, 2026

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

An interventional study of High-Dose Rate Brachytherapy and Proton Beam Radiation Therapy in Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 and Stage IIIB Prostate Cancer AJCC v8, sponsored by Emory University. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Prostatic Neoplasms by Emory University — 7 open to participants now, 9 under way, 1 of them phase 3. Prostatic Neoplasms · Emory University.

Planned enrollment
13th of 25
30 · median 30
Started
2021
the only one that year
No phase
10 of 25
4 open now
Registered
16th of 25
by date

Among the 25 studies in Prostatic Neoplasms by Emory University, this one is the 13th largest by planned enrollment, is the only one that started in 2021, is one of 10 with no phase, and was the 16th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 25 studies in Prostatic Neoplasms by Emory University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Prostatic Neoplasms by Emory University, or all of them as a file.
02

Study summary

This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with high-risk or lymph node positive prostate cancer who are receiving radiation therapy, and if it will result in fewer gastrointestinal and genitourinary side effects. Proton beam therapy is a new type of radiotherapy that directs multiple beams of protons (positively charged subatomic particles) at the tumor target, where they deposit the bulk of their energy with essentially no residual radiation beyond the tumor. By reducing the exposure of the healthy tissues and organs to radiation in the treatment of prostate cancer, proton therapy has the potential to better spare healthy tissue and reduce the side effects of radiation therapy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the rate of acute grade 2+ gastrointestinal toxicity compared to historical photon treatments.

SECONDARY OBJECTIVES:

I. To determine the rate of acute grade 2+ genitourinary toxicity compared to historical photon treatments.

II. To assess the feasibility of extended-field proton irradiation of high-risk prostate.

III. To demonstrate safety of proton therapy followed by high dose rate (HDR) boost.

IV. To determine patient-reported outcomes (PROs) of toxicity.

OUTLINE:

Patients undergo conventionally fractionated proton beam therapy daily on Monday-Friday. Patients may receive a high-dose rate brachytherapy boost.

After completion of study treatment, patients are followed up at 1, 3, 6, 9 and 12 months, and 1.5, 2, 2.5, and 3 years.

03

Conditions studied

  • Stage III Prostate Cancer AJCC v8
  • Stage IIIA Prostate Cancer AJCC v8
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed high-risk prostate cancer fulfilling any one of the following criteria:

    • Gleason grade 8 or higher
    • cT3b (seminal vesicle involvement) or cT4
    • Prostate specific antigen [PSA] > 20 (or PSA >10 if on finasteride)
    • Clinically or pathologically positive regional lymph nodes within the inguinal, external iliac, internal iliac, obturator, peri-rectal, pre-sacral, common iliac, or lower para-oaortc (inferior to the L2-L3 interspace) basins
  • Zubrod performance status 0-2
  • Complete blood cell (CBC)/differential obtained within 90 days prior to registration on study
  • (ANC) >= 1,500 cells/mm\^3
  • >= 100,000 cells/mm\^3
  • >= 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
  • Patient must be able to provide study specific

Exclusion criteria

Exclusion Criteria:

  • Absence of bone by bone scan or metabolic imaging (e.g. NaF PET, FACBC PET, PSMA PET, etc.) before the start of therapy.
  • Absence of distant lymph node metastasis by CT and/or MRI before the start of therapy.
  • Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
  • Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
  • Uncontrolled intercurrent illness including, but not limited to, inflammatory bowel disease, infection, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment (proton beam therapy)

    Patients undergo conventionally fractionated or hypofractionated proton beam therapy daily on Monday-Friday directed to the prostate, pelvic lymph nodes, and para-aortic lymph nodes. Patients may receive an optional high-dose rate brachytherapy boost. Androgen deprivation therapy is required but left to the discretion of the treating physician.

    Radiation: High-Dose Rate Brachytherapy · Radiation: Proton Beam Radiation Therapy · Other: Quality-of-Life Assessment · Other: Survey Administration

Interventions

  • RadiationHigh-Dose Rate Brachytherapy

    Receive high-dose rate brachytherapy boost

    Also known as: Brachytherapy, High Dose

  • RadiationProton Beam Radiation Therapy

    Undergo proton beam therapy

    Also known as: PBRT, Proton, Proton Radiation Therapy, Radiation, Proton Beam

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Acute grade 2+ gastrointestinal (GI) toxicity

    The rate of grade 2+ gastrointestinal toxicity within 30 days of receiving radiation therapy (RT) will be measured. It will be compared to the theorized reduction to 24% toxicity using the exact binomial test. Assessments are based on version 5 Common Terminology Criteria for Adverse Events (CTCAE), and the worst severity of GI toxicity will be assessed.

    Time frame: Up to 3 years

Secondary outcomes

  1. Acute grade 2+ genitourinary (GU) toxicity rate

    The rate of grade 2+ genitourinary toxicity within 30 days of receiving radiation therapy (RT) will be measured. Assessments are based on version 5 CTCAE, and the worst severity of GU toxicity will also be assessed.

    Time frame: Up to 3 years

  2. Optimal frequency of cone beam computed tomography (CT)

    Will determine the optimal frequency of cone beam CT during treatment and assess subsequent need for adaptive re-planning. The feasibility of extended-field proton irradiation of high-risk prostate cancer will be estimated using a re-planning rate of less than 10%. The re-planning rate will be estimated as binary variable, yes or no. The exact 95% confidence interval (CI) around the 10 % re-planning count based on the binomial distribution for the estimated 30 patients will be used (0.021-0.265). The study will be deemed feasible if the observed rate is not higher than the upper bound of the estimated 95% CI.

    Time frame: Through study completion, an average of 1 year

  3. Patient reported health related quality of life (QOL) - PRO-CTCAU GI

    Assessed using Patient Reported Outcomes-CTCAE GI toxicity

    Time frame: Up to 3 years

  4. Patient reported health related quality of life (QOL) - PRO-CTCAU GU

    Assessed using Patient Reported Outcomes-CTCAE GU toxicity

    Time frame: Up to 3 years

  5. Patient reported health related quality of life (QOL) - IPSS

    International Prostate Symptom Score (IPSS)

    Time frame: Up to 3 years

  6. Patient reported health related quality of life (QOL) - EPIC-CP

    Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP)

    Time frame: Up to 3 years

  7. Chronic GI Toxicity

    The rate of any grade gastrointestinal toxicity occurring after 90 days from the completion of radiation therapy(RT). Assessments are based on version 5 Common Terminology Criteria for Adverse Events (CTCAE), and the worst severity of GI toxicity will be assessed.

    Time frame: Up to 3 years

  8. Chronic GU Toxicity

    The rate of any grade genitourinary toxicity occurring after 90 days from the completion of radiation therapy(RT). Assessments are based on version 5 Common Terminology Criteria for Adverse Events (CTCAE), and the worst severity of GU toxicity will be assessed.

    Time frame: Up to 3 years

  9. Biochemical failure

    Assessed by the Phoenix definition (prostate specific antigen \[PSA\] \>= 2 ng/ml over the nadir PSA).

    Time frame: Baseline up to pre-RT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 70 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2021
First posted
Jan 27, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04725903
Lead sponsor
Emory University
Responsible party
Pretesh Patel (Principal Investigator, Emory University) — Principal investigator
First posted
Jan 27, 2021
Start date
Feb 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Pretesh Patel, MD
Contact
pretesh.patel@emory.edu
404-778-3473
Pretesh R Patel
principal investigator · Emory University Hospital/Winship Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion